Services

Capital 33 provides advisory, transaction, capital, and private equity services to smaller middle market companies—$5 to $50 million revenue—to improve performance, accelerate growth, evaluate an exit, or complete an exit.

The Capital 33 difference is in combining advisory and transaction services, and offering depth in both.

Read More

Clients

Capital 33’s clients are smaller middle market companies that are:

• At a plateau in growth

• Experiencing operational or cost challenges

• Wanting new avenues to growth

• Looking to raise capital for growth

• Evaluating exit opportunities

Our clients often are family-owned, entrepreneur-founded, or investor-backed. We’re most experienced with companies in the business services, distribution, manufacturing, healthcare, retail, e-commerce, and technology sectors.

Read More

Difference

The Capital 33 difference is in combining advisory and transaction services, and offering depth in both. Many firms focus only on consulting or M&A. Cap 33 is also nimble, moving faster than large consulting and finance firms, and can offer fee structures and phasing that allow mid-size companies access to services they may not otherwise pursue.

• Experience as founders, and operating and marketing executives—we understand client perspectives, challenges, and interests

• Deep functional expertise in strategy, operations, sales & marketing, finance

• Bought and sold 10-plus companies

• Raised over $70 million in debt/equity capital for companies where we have been advisers, owners, and executives

• Most recent M&A transaction was representing the seller of a $17-million Denver distribution business in sale to a strategic buyer

• Most recent capital raise was $1.5 million in equity for a Denver consumer healthcare company

Read More

denverpost

Denver Post: London Stock Exchange in Denver for Capital 33 event

On January 19, 2015, the Denver Post published an article discussing how representatives from London Stock Exchange have begun recruiting business in Denver to list on the LSE’s international market for growth companies, AIM. Following the journey of Cell>Point, a Colorado-based biotech company, the article highlights some of the major benefits of AIM as compared […]

Read More